Holen Sie sich die Stockscreener-App
1.77
1.12%
-0.02
Handel nachbörslich:
1.78
0.01
+0.56%
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Q1 2025 Ocugen Inc Earnings Call Transcript - gurufocus.com
Ocugen (OCGN) has a healthy cash position for 2026 - MSN
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress - Yahoo Finance
Ocugen, Inc. (OCGN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Assessing Ocugen (OCGN) Valuation After Strong One Year Share Price Momentum - Sahm
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - investing.com
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN - MarketBeat
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com
Director Zhang Junge exercises 194,134 Ocugen (OCGN) options, lifts direct stake to 1.36M shares - Stock Titan
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - The Globe and Mail
OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - bitget.com
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program - Sahm
Ocugen Achieves Key Enrollment Target in Stargardt Disease Gene Therapy Trial - AD HOC NEWS
Ocugen completes enrollment in Stargardt disease gene therapy trial By Investing.com - Investing.com Australia
Ocugen Inc. stock falls Wednesday, underperforms market - marketwatch.com
$Ocugen (OCGN.US)$ - Moomoo
Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | Ocugen, Inc. - Ocugen, Inc.
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease - Ophthalmology Times
Ocugen (OCGN) Completes Dosing in Key Clinical Trial for Stargar - GuruFocus
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease - marketscreener.com
Ocugen completes enrollment in Stargardt disease gene therapy trial - Investing.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - ChartMill
Block Trades: What is the next catalyst for Ocugen IncEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden - Traders Union
Ocugen Inc. stock rises Tuesday, outperforms market - marketwatch.com
OCGN PE Ratio & Valuation, Is OCGN Overvalued - Intellectia AI
Ocugen (OCGN) Reveals OCU410 Clinical Trial Data - insidermonkey.com
Ocugen, Inc. (NASDAQ:OCGN) Q3 2025 Earnings Call Transcript - MSN
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Retinal specialists drive clinical progress on modifier gene therapy, Ocugen, Inc. asserts - Traders Union
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Risk Recap: Is Ocugen Inc undervalued by DCF analysisMarket Risk Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations - Yahoo Finance
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood - Insider Monkey
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (OCGN) disaggregates holdings; reports 0% ownership in Ocugen - Stock Titan
Can Ocugen succeed where other gene therapy makers have struggled? - Pharma Voice
Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies - TipRanks
What is Noble Financial's Estimate for Ocugen Q3 Earnings? - MarketBeat
HC Wainwright Issues Positive Forecast for Ocugen Earnings - MarketBeat
Ocugen posts investor presentation outlining progress across three gene-therapy BLAs, Phase 3 enrollment and positive Phase 2/3 data - TradingView
Ocugen (OCGN) showcases retinal gene therapy pipeline with new OCU410 Phase 2 data - Stock Titan
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen appoints Rita Johnson-Greene as chief financial officer - MSN
Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital - MarketBeat
Ocugen (OCGN) Stock Maintained at Buy Rating by Chardan Capital - GuruFocus
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):